Related Experiment Video
Updated: Jul 10, 2025
04:50
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
Published on: January 17, 2025
243
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
Ingrid Garajová1, Fabio Gelsomino2, Massimiliano Salati2
1Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy.
Life (Basel, Switzerland)
|November 25, 2023
Summary
Second-line chemotherapy offers benefits for select advanced intrahepatic cholangiocarcinoma patients. Patient selection based on performance status and first-line treatment response is crucial for improved outcomes.
Area of Science:
- Oncology
- Gastroenterology
- Cancer Research
Background:
- Advanced biliary tract cancers present limited therapeutic options.
- Actionable alterations enable targeted second-line treatments.
- Chemotherapy remains the primary option for many patients.
Purpose of the Study:
- To evaluate outcomes and prognostic factors for intrahepatic cholangiocarcinoma (ICC) patients receiving second-line chemotherapy.
- To identify patient subgroups who benefit most from subsequent treatment lines.
Main Methods:
- Retrospective review of 255 metastatic ICC patients.
- Collection of clinicopathologic and survival data.
- Analysis of factors influencing treatment decisions and outcomes.
Main Results:
- 44% of ICC patients received second-line chemotherapy.
- Younger patients with better ECOG PS and disease control post-first-line were selected.
- Median progression-free survival was 3 months for those on second-line therapy.
- Positive prognostic factors included better ECOG PS, prior surgery, first-line response, and progression-free survival.
Conclusions:
- Second-line chemotherapy benefits are not universal in advanced ICC.
- Performance status and first-line treatment response are key indicators for second-line treatment efficacy.
- Informed therapeutic decisions require careful patient selection.
